Alecta Tjanstepension Omsesidigt Has $219.97 Million Stake in Danaher Corporation $DHR

Key Points

• Alecta Tjanstepension Omsesidigt sold 419,000 shares of Danaher Corporation, reducing its holdings by 27.3% to own approximately 1,114,000 shares valued at $219.97 million.
• Insider transactions included Director Teri List selling 2,778 shares at an average price of $211.06, representing an 11.81% decrease in her position.
• Analysts have mixed ratings on Danaher, with price targets ranging from $225 to $275 and a consensus average rating of "Moderate Buy."

Alecta Tjanstepension Omsesidigt lowered its stake in Danaher Corporation (NYSE:DHR - Free Report) by 27.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,114,000 shares of the conglomerate's stock after selling 419,000 shares during the quarter. Alecta Tjanstepension Omsesidigt owned approximately 0.16% of Danaher worth $219,970,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after acquiring an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after acquiring an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after acquiring an additional 194,466 shares in the last quarter. Invesco Ltd. grew its stake in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after acquiring an additional 163,332 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

Shares of DHR stock traded down $1.96 during trading hours on Friday, reaching $193.31. 5,932,115 shares of the company's stock were exchanged, compared to its average volume of 3,243,103. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The stock has a market capitalization of $138.42 billion, a P/E ratio of 41.13, a P/E/G ratio of 2.72 and a beta of 0.75. The business has a fifty day moving average price of $200.17 and a 200-day moving average price of $198.39. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the company earned $1.72 earnings per share. The company's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DHR shares. Guggenheim reaffirmed a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Finally, Evercore ISI lowered their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.